{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:26:37Z","timestamp":1778055997864,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.jaad.2005.01.093","type":"journal-article","created":{"date-parts":[[2005,4,27]],"date-time":"2005-04-27T07:41:32Z","timestamp":1114587692000},"page":"847-853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Treatment of primary cutaneous B-cell lymphoma with rituximab"],"prefix":"10.1016","volume":"52","author":[{"given":"Regina","family":"Fink-Puches","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid H.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Zalaudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Kerl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Cerroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2005.01.093_bib1","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood.V99.3.800","article-title":"Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients","volume":"99","author":"Fink-Puches","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2005.01.093_bib2","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2005.01.093_bib3","series-title":"An illustrated guide to skin lymphoma","author":"Cerroni","year":"2004"},{"key":"10.1016\/j.jaad.2005.01.093_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdermsci.2003.10.008","article-title":"Diagnostic principles and new developments in primary cutaneous B-cell lymphomas","volume":"34","author":"Kerl","year":"2004","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2005.01.093_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s001050050005","article-title":"Die Therapie der prim\u00e4ren kutanen B-Zell Lymphome. [Therapy of primary cutaneous B-cell lymphomas]","volume":"51","author":"Zenahlik","year":"2000","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2005.01.093_bib6","first-page":"366","article-title":"Therapy of cutaneous lymphoma\u2014current practice and future developments","volume":"26","author":"Dummer","year":"2003","journal-title":"Onkologie"},{"key":"10.1016\/j.jaad.2005.01.093_bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2005.01.093_bib8","first-page":"62","article-title":"Immunohistological markers for the diagnosis of cutaneous lymphomas","volume":"8","author":"Ralfkiaer","year":"1991","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.jaad.2005.01.093_bib9","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant B-cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2005.01.093_bib10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody","volume":"10","author":"Leget","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib11","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to four dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1034\/j.1600-0560.2003.00078.x","article-title":"Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy","volume":"30","author":"Clarke","year":"2003","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2005.01.093_bib13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/sonc.2002.30152","article-title":"Rituximab in combination with CHOP or fludarabine in low-grade lymphoma","volume":"29","author":"Czuczman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib15","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib16","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s002770100314","article-title":"Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab","volume":"80","author":"Ferrer","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaad.2005.01.093_bib18","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib19","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2005.01.093_bib20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib21","first-page":"1152","article-title":"Cutaneous B-cell lymphoma treatment with rituximab: two cases","volume":"129","author":"Viguier","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2005.01.093_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2005.01.093_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2230.2003.01132.x","article-title":"Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP)","volume":"28","author":"Schmook","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2005.01.093_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archderm.136.3.374","article-title":"Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma","volume":"136","author":"Heinzerling","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2005.01.093_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1046\/j.1365-2133.2001.04241.x","article-title":"Intralesional Rituximab for cutaneous B-cell lymphoma","volume":"144","author":"Paul","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2005.01.093_bib26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00000421-200106000-00005","article-title":"Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab)","volume":"24","author":"Aboulafia","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00432-001-0313-2","article-title":"Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab","volume":"128","author":"Bonnekoh","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/S0190-9622(03)00889-2","article-title":"Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series","volume":"49","author":"Brogan","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.01.093_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.0007-0963.2001.04520.x","article-title":"Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer","volume":"146","author":"Garbea","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2005.01.093_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s001050051291","article-title":"Der Anti-CD20-Antik\u00f6rper bei prim\u00e4r kutanen B-Zell Lymphomen. Erste Erfahrungen in der dermatologischen Anwendung","volume":"52","author":"Gellrich","year":"2001","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2005.01.093_bib31","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H","article-title":"Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma","volume":"89","author":"Heinzerling","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2005.01.093_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1067\/mjd.2002.108490","article-title":"CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy","volume":"46","author":"Massengale","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.01.093_bib33","first-page":"1835","article-title":"Rituximab in cutaneous B-cell lymphoma: a report of two cases","volume":"89","author":"Sabroe","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2005.01.093_bib34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1067\/mjd.2002.124076","article-title":"Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas","volume":"47","author":"Shapiro","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.01.093_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/000155501750376339","article-title":"Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody","volume":"81","author":"Soda","year":"2001","journal-title":"Acta Derm Venereol"},{"issue":"1 Suppl. 2","key":"10.1016\/j.jaad.2005.01.093_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2005.01.093_bib37","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/1042819021000040044","article-title":"Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study","volume":"43","author":"Chu","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaad.2005.01.093_bib38","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdf350","article-title":"Stevens-Johnson syndrome after treatment with rituximab","volume":"13","author":"Lowndes","year":"2002","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.jaad.2005.01.093_bib39","first-page":"12","article-title":"Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies","volume":"36","author":"Rai","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jaad.2005.01.093_bib40","first-page":"3916","article-title":"CD20-negative relapse in B-cell lymphoma after treatment with Rituximab","volume":"16","author":"Kinoshita","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205004263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205004263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:38:26Z","timestamp":1759268306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962205004263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0190962205004263"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2005.01.093","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of primary cutaneous B-cell lymphoma with rituximab","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2005.01.093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}